These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26675495)

  • 21. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
    Johnston SR
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26251289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
    Qiao L; Liang Y; Mira RR; Lu Y; Gu J; Zheng Q
    Int J Clin Exp Med; 2014; 7(10):3333-43. PubMed ID: 25419366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.
    Paplomata E; O'Regan R
    Ther Clin Risk Manag; 2013; 9():27-36. PubMed ID: 23345981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
    Brufsky AM; Dickler MN
    Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.
    Cortés J; Im SA; Holgado E; Perez-Garcia JM; Schmid P; Chavez-MacGregor M
    Cancer Treat Rev; 2017 Dec; 61():53-60. PubMed ID: 29100169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging treatment combinations: integrating therapy into clinical practice.
    Wong ST
    Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S9-S14. PubMed ID: 19923318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
    Sun B; Ding L; Wu S; Meng X; Song S
    Onco Targets Ther; 2016; 9():3997-4003. PubMed ID: 27445490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
    Ciruelos E; Cortes-Funes H; Ghanem I; Manso L; Arteaga C
    Anticancer Drugs; 2013 Sep; 24(8):769-80. PubMed ID: 23838677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment.
    LoRusso PM
    Oncology; 2013; 84(1):43-56. PubMed ID: 23128843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer.
    du Rusquec P; Blonz C; Frenel JS; Campone M
    Ther Adv Med Oncol; 2020; 12():1758835920940939. PubMed ID: 32782489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
    Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
    Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.
    Villarreal-Garza C; Cortes J; Andre F; Verma S
    Ann Oncol; 2012 Oct; 23(10):2526-2535. PubMed ID: 22553196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR inhibitors in the treatment of breast cancer.
    Vinayak S; Carlson RW
    Oncology (Williston Park); 2013 Jan; 27(1):38-44, 46, 48 passim. PubMed ID: 23461041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
    BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.